Postoperative surveillance of differentiated thyroid carcinoma: Rationale, techniques, and controversies 1

Radiology

Volumn 249, Issue 2, 2008, Pages 429-444

  Johnson, Nathan A ^a   Tublin, Mitchell E ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; THYROGLOBULIN;

ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; ECHOGRAPHY; HEALTH SURVEY; HORMONAL THERAPY; INCIDENCE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; THYROID CARCINOMA; THYROIDECTOMY; BLOOD; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DOPPLER FLOWMETRY; HUMAN; METHODOLOGY; PATHOLOGY; POSTOPERATIVE PERIOD; PREDICTION AND FORECASTING; PROGNOSIS; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TUMOR RECURRENCE;

DIAGNOSTIC IMAGING; HUMANS; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER;

EID: 56149098260     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2492071313     Document Type: Article

References (113)

1. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97(5):418-428.
2. Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940 - 1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg 2002; 26(8):879-885.
3. Torlontano M, Crocetti U, Augello G, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006; 91(1):60-63.
4. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150(2): 105-112.
5. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003; 88(8):3668-3673.
6. Stulak JM, Grant CS, Farley DR, et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative thyroid cancer. Arch Surg 2006; 141(5):489-496.
7. Kouvaraki MA, Shapiro SE, Fornage BD, et al. Role of preoperative ultrasonography in the surgicalmanagement of patients with thyroid cancer. Surgery 2003;134(6):946-954.
8. Bhattacharyya N. Surgical treatment of cervical nodal metastases in patients with papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2003;129(10):1101-1104.
9. Caron NR, Tan YY, Ogilvie JB, et al. Selective modified radical neck dissection for papillary thyroid cancer: is level I, II, and V dissection always necessary? World J Surg 2006;30(5):833-840.
10. Palazzo FF, Gosnell J, Savio R, et al. Lymphadenectomy for papillary thyroid cancer: changes in practice over four decades. Eur J Surg Oncol 2006;32(3):340-344.
11. Baskin HJ. New applications of thyroid and parathyroid ultrasound. Minerva Endocrinol 2004;29(4):195-206.
12. Lewis BD, HayID, CharboneauJW, McIver B, Reading CC, Goellner JR. Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. AJR Am J Roentgenol2002;178(3): 699-704.
13. Monchik JM, Donatini G, Iannuccilli J, Dupuy DE. Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. Ann Surg 2006;244(2):296-304.
14. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States: 1973-2002. JAMA 2006;295(18):2164-2167.
15. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States in 1996. Cancer 2000;89(1):202-217.
16. Haq M, Harmer C. Differentiated thyroid carcinoma with distant metastases at presentation: prognostic factors and outcome. Clin Endocrinol (Oxf) 2005;63(1):87-93.
17. Lin JD, Huang MJ, Juang JH, et al. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases. Thyroid 1999;9(12):1227-1235.
18. Benbassat CA, Mechli-Frish S, Hirsch D. Clini-copathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg 2006;30(6):1088-1095.
19. Ilgan S, Karacalioglu AO, Pabuscu Y, et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2004;31(6):825-830.
20. Schirrmeister H, Buck A, Guhlmann A, Reske SN. Anatomical distribution of sclerotic activity of bone metastases from thyroid cancer assessed with F-18 sodium fluoride positron emission tomography. Thyroid 2001;11(7):677-683.
21. Cross S, Wei JP, Kim S, Brams DM. Selective surgery and adjuvant therapy based on risk classifications of well-differentiated thyroid cancer. J Surg Oncol 2006;94(8):678-682.
22. Kovacs GL, Gonda G, Vadasz G, et al. Epidemiology of thyroid microcarcinoma found in autopsy series conducted in areas of different iodine intake. Thyroid 2005;15(2):152-157.
23. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma ofthe thyroid: a "normal" finding in Finland-a systematic autopsy study. Cancer 1985;56(3):531-538.
24. Komorowski RA, Hanson GA. Occult thyroid pathology in the young adult: an autopsy study of 138 patients without clinical thyroid disease. Hum Pathol 1988;19(6):689-696.
25. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003;13(4):381-387.
26. Jukkola A, Bloigu R, Ebeling T, et al. Prognostic factors in differentiated thyroid carcinomas and their implications for current staging classifications. Endocr Relat Cancer 2004;11(3):571-579.
27. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab 1997;82(11):3553-3562.
28. Rouxel A, Hejblum G, Bernier MO, et al. Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2004;89(11):5362- 5368.
29. Durante C, Haddy N, Baudin E, et al. Longterm outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892-2899.
30. Beasley NJ, Lee J, Eski S, Walfish P, Witterick I, Freeman JL. Impact of nodal metastases on prognosis in patients with well-differentiated thyroid cancer. Arch Otolaryngol Head Neck Surg 2002;128(7):825-828.
31. CooperDS, DohertyGM, HaugenBR, etal. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109-142.
32. Sosa JA, Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol 2006;94(8):701-707.
33. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL. Surgeon-performed ultrasound in the management ofthyroid malignancy. Am Surg 2004;70(7):576-580.
34. Dackiw AP, Zeiger M. Extent of surgery for differentiated thyroid cancer. Surg Clin North Am 2004;84(3):817-832.
35. Gemsenjager E, Perren A, Seifert B, Schuler G, Schweizer I, Heitz PV. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003;197(2):182-190.
36. Cheah WK, Arici C, Ituarte PH, Siperstein AE, Duh QY, Clark OH. Complications of neck dissection for thyroid cancer. World J Surg 2002;26(8):1013-1016.
37. Kebebew E, Clark OH. Differentiated thyroid cancer: "complete" rational approach. World J Surg 2000;24(8):942-951.
38. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 1962;87:171-182.
39. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89(8):3668-3676.
40. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87(4):1490-1498.
41. 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2005;90(3):1440-1445.
42. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88(4):1433-1441.
43. Van Tol KM, Jager PL, de Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003;148(6):589-596.
44. 131I whole-body scanning results? J Nucl Med 2005;46(7): 1164-1170.
45. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003;97(1):90-96.
46. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81(12):4318-4323.
47. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the national thyroid cancer treatment cooperative registry. Thyroid 1998;8(9):737-744.
48. Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61(1):61-74.
49. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002;87(2):489-499.
50. Rubello D, CasaraD, GirelliME, Piccolo M, Busnardo B. Clinical meaning of circulating anti-thyroglobulin antibodies in differentiated thyroid cancer: a prospective study. J NuclMed 1992;33(8):1478-1480.
51. Gorges R, Maniecki M, Jentzen W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005;153(1):49-55.
52. Fugazzola L, Mihalich A, Persani L, et al. Highly sensitive serum thyroglobulin and circulating thyroglobulin mRNA evaluations in the management of patients with differentiated thyroid cancer in apparent remission. J Clin Endocrinol Metab 2002;87(7): 3201-3208.
53. Grammatopoulos D, Elliott Y, Smith SC, et al. Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer. Mol Pathol 2003;56(3):162-166.
54. Milas M, Mazzaglia P, Chia SY, et al. The utility of peripheral thyrotropin mRNA in the diagnosis of follicular neoplasms and surveillance of thyroid cancers. Surgery 2007;141(2):137-146.
55. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000;85(1):175-178.
56. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinehera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg level after initial treatment. J Clin Endocrinol Metab 2002; 87(4):1499-1501.
57. Fatourechi V, Hay ID. Treating the patient with differentiated thyroid cancer with thyroglobulin-positive iodine-131 diagnostic scan-negative metastases: including comments on the role of serum thyroglobulin monitoring in tumor surveillance. Semin NuclMed 2000;30(2):107-114.
58. 131I. J Nucl Med 2000;41(7): 1198-1202.
59. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning. Radiology 2004;232(2):527-533.
60. 123I versus 131I preablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nucl Med 2007;48(7):1043-1046.
61. Som PM, Curtin HD, Mancuso AA. Image-based nodal classification for evaluation of neck metastatic adenopathy. AJR Am J Roentgenol2000;174(3):837- 845.
62. Rosario PW, de Faria S, Bicalho L, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005;24(10):1385-1389.
63. Kuna SK, Bracic I, Tesic V, Kuna K, Herceg GH, Dodig D. Ultrasonographic differentiation of benign from malignant neck lymph-adenopathy in thyroid cancer. J Ultrasound Med 2006;25(12):1531-1537.
64. Lee JH, Lee HK, Lee DH, et al. Ultrasonographic findings of a newly detected nodule on the thyroid bed in postoperative patients for thyroid carcinoma: correlation with the results of ultrasonography-guided fine-needle aspiration biopsy. Clin Imaging 2007; 31(2):109-113.
65. Kessler A, Rappaport Y, Blank A, Marmor S, Weiss J, Graif M. Cystic appearance of cervical lymph nodes is characteristic of metastatic papillary thyroid carcinoma. J Clin Ultrasound 2003;31(1):21-25.
66. Wunderbaldinger P, Harisinghani MG, Hahn PF, et al. Cystic lymph node metastases in papillary thyroid carcinoma. AJR Am J Roentgenol2002;178(3):693- 697.
67. Ahuja AT, Ying M, Yuen HY, Metreweli C. Power Doppler sonography of metastatic nodes from carcinoma of the thyroid. Clin Radiol2001;56(4):284-288.
68. Lyshchik A, Higashi T, Asato R, et al. Cervical lymph node metastases: diagnosis at sonoelastography-initial experience. Radiology2007;243(1):258-267.
69. Uruno T, Miyauchi A, Shimizu K, et al. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J Surg 2005;29(4):483-485.
70. Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid 2004;14(11):959-963.
71. Cignarelli M, Ambrosi A, Marino A, et al. Diagnostic utility of thyroglobulin detection in fine-needle aspiration of cervical cystic metastatic lymph nodes from papillary thyroid cancer with negative cytology. Thyroid 2003;13(12):1163-1167.
72. Ito Y, Tomoda C, Uruno T, et al. Ultrasono-graphically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg 2005;29(7):917-920.
73. Ito Y, Tomoda C, Uruno T, et al. Clinical significance of metastasis to the central compartment from papillary microcarci-noma of the thyroid. World J Surg 2006; 30(7):91-99.
74. Noguchi S, Noguchi A, Murakami N. Papillary carcinoma of the thyroid. II. Value of prophylactic lymph node dissection. Cancer 1970;26(5):1061-1064.
75. Lazar V, Bidart JM, Caillou B, et al. Expression of the Na+/I-symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin EndocrinolMetab1999;84(9):3228-3234.
76. 18F] fluorodeoxyglu-cose positron emission tomographic scanning in patients with thyroid cancer. J Clin EndocrinolMetab2000;85(3):1107-1113.
77. Leboulleux S, Schroeder PR, Schlumberger M, Ladenson PW. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nat Clin Pract EndocrinolMetab2007;3(2):112-121.
78. Khan N, Oriuchi N, Higuchi T, Zhang H, Endo K. PET in the follow-up of differentiated thyroid cancer. Br J Radiol 2003;76(910):690-695.
79. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Fluorine-18 fluorodeoxy glucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24(11):1342-1348.
80. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 2001;42(1):71-76.
81. 18F]fluorodeoxyglucose positron emission tomography in follow-up of differentiated thyroid cancer. Endocr Pract 2006;12(2):152-158.
82. 18F]-2-fluoro-2- deoxy-d-gucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic carcinoma in patients with no detectable radioiodine uptake? Eur J Endocrinol 2003;149(4):293-300.
83. Grunwald F, Kalicke T, Feine U, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26(12):1547-1552.
84. Palmedo H, Bucerius J, Joe A, et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 2006;47(4):616-624.
85. 18F-FDG PET/CTforthe initialeval-uation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. Clin Endocrinol (Oxf) 2006;65(3):402-407.
86. 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 2007;48(2):221-226.
87. Nahas Z, Goldenberg D, Fakhry C, et al. The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 2005;115(2):237-243.
88. 131I-negative papillary thyroid carcinoma. Thyroid 2006;16(3):267-272.
89. 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84(7):2291-2302.
90. 131I scanning results after therapy. J Nucl Med 2001;42(10): 1464-1469.
91. Weber AL, Randolph G, Aksoy FG. The thyroid and parathyroid glands. CT and MR imaging and correlation with pathology and clinical findings. Radiol Clin North Am 2000;38(5):1105-1129.
92. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality? Eur J Nucl Med Mol Imaging 2007;34(4):487-495.
93. Takashima S, Takayama F, Wang J, Kobayashi S, Kadoya M. Using MR imaging to predict invasion of the recurrent laryngeal nerve by thyroid carcinoma. AJR Am J Roentgenol 2003;180(3):837-842.
94. Takashima S, Takayama F, Wang Q, et al. Differentiated thyroid carcinomas: prediction of tumor invasion with MR imaging. Acta Radiol2000;41(4):377-383.
95. Wang JC, Takashima S, Takayama F, et al. Trachealinvasion by thyroid carcinoma: prediction using MR imaging. AJR Am J Roentgenol2001;177(4):929-936.
96. King AD, Ahuja AT, To EW, Tse GM, Metreweli C. Staging papillary carcinoma of the thyroid: magnetic resonance imaging versus ultrasound of the neck. Clin Radiol 2000;55(3):222-226.
97. Takashima S, Sone S, Takayama F, et al. Papillary thyroid carcinoma: MR diagnosis of lymph node metastases. AJNR Am J Neuroradiol1998;19(3):509-513.
98. Gross ND, Weissman JL, Talbot JM, Andersen PE, Wax MK, Cohen JI. MRI detection of cervical metastasis from differen-tiated thyroid carcinoma. Laryngoscope 2001;111(11 pt1):1905-1909.
99. Shah GV, Fischbein NJ, Patel R, Mukherji SK. Newer MR imaging techniques for head and neck. Magn Reson Imaging Clin N Am 2003;11(3):449-469.
100. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63(7):1454-1457.
101. Groussin L, Fagin JA. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat Clin Pract Endocrinol Metab 2006; 2(4):180-181.
102. Kim J, Giuliano AE, Turner RR, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006;244(5):799-804.
103. Kim TY, Kim WB, Song JY, et al. The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005;63(5):588-593.
104. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006;65(3):364-368.
105. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90(12): 6373-6379.
106. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, Nistal M, Santisteban P. The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I-targeting to the membrane. Endocr Relat Cancer 2006;13(1):257-269.
107. Xing M, Tufano RP, Tufaro AP, et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J Clin Endocrinol Metab 2004;89(6):2867-2872.
108. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/ PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab 2004;89(10):5175-5180.
109. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr Pathol 2002;13(1): 3-16.
110. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol2006;30(2):216- 222.
111. Santoro M, Carlomagno F. Drug insight: small-molecule inhibitors ofprotein kinases in the treatment ofthyroid cancer. Nat Clin Pract Endocrinol Metab 2006;2(1):42-52.
112. Espinosa AV, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96(1):16-20.
113. Ouyang B, Knauf JA, Smith EP, et al. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo. Clin Cancer Res 2006;12(6):1785-1793.